Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy

To evaluate the effect of ruboxistaurin, an orally administered protein kinase C beta (PKC beta) isozyme-selective inhibitor, on vision loss in patients with diabetes. Thirty-six-month, randomized, double-masked, placebo-controlled, parallel, multicenter trial. Six hundred eighty-five patients rando...

Full description

Saved in:

Bibliographic Details
Published in:	Ophthalmology (Rochester, Minn.) Vol. 113; no. 12; p. 2221
Main Authors:	Aiello, Lloyd Paul, Davis, Matthew D, Girach, Aniz, Kles, Keri A, Milton, Roy C, Sheetz, Matthew J, Vignati, Louis, Zhi, Xin Eric
Format:	Journal Article
Language:	English
Published:	United States 01.12.2006
Subjects:	Administration, Oral Adult Aged Aged, 80 and over Diabetic Retinopathy - drug therapy Disease Progression Double-Blind Method Enzyme Inhibitors - adverse effects Enzyme Inhibitors - therapeutic use Female Humans Indoles - adverse effects Indoles - therapeutic use Macular Edema - drug therapy Macular Edema - physiopathology Male Maleimides - adverse effects Maleimides - therapeutic use Middle Aged Protein Kinase C - antagonists & inhibitors Protein Kinase C beta Vision Disorders - prevention & control Visual Acuity - drug effects
ISSN:	1549-4713, 1549-4713
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!